286 related articles for article (PubMed ID: 12640663)
1. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ; Seligson DB; Liu AY; Pantuck AJ; Paik SH; Horvath S; Wieder JA; Zisman A; Nguyen D; Tso CL; Palotie AV; Belldegrun AS
Prostate; 2003 Apr; 55(1):71-80. PubMed ID: 12640663
[TBL] [Abstract][Full Text] [Related]
2. Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
Song J; Aumüller G; Xiao F; Wilhelm B; Albrecht M
Prostate; 2004 Mar; 58(4):394-405. PubMed ID: 14968440
[TBL] [Abstract][Full Text] [Related]
3. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
4. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
6. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Fujinami K; Uemura H; Ishiguro H; Kubota Y
Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
[TBL] [Abstract][Full Text] [Related]
7. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
8. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
10. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
11. Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Liu AY; Brubaker KD; Goo YA; Quinn JE; Kral S; Sorensen CM; Vessella RL; Belldegrun AS; Hood LE
Prostate; 2004 Jul; 60(2):98-108. PubMed ID: 15162376
[TBL] [Abstract][Full Text] [Related]
12. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
13. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
14. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Albrecht M; Gillen S; Wilhelm B; Doroszewicz J; Aumüller G
J Urol; 2002 Jul; 168(1):336-42. PubMed ID: 12050566
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
Yousef GM; Stephan C; Scorilas A; Ellatif MA; Jung K; Kristiansen G; Jung M; Polymeris ME; Diamandis EP
Prostate; 2003 Sep; 56(4):287-92. PubMed ID: 12858357
[TBL] [Abstract][Full Text] [Related]
16. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
17. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
Osman I; Dai J; Mikhail M; Navarro D; Taneja SS; Lee P; Christos P; Shen R; Nanus DM
Cancer; 2006 Dec; 107(11):2628-36. PubMed ID: 17083125
[TBL] [Abstract][Full Text] [Related]
18. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
Mink SR; Hodge A; Agus DB; Jain A; Gross ME
Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
[TBL] [Abstract][Full Text] [Related]
19. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
20. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
